METHACHOLINE CHLORIDE, USP POWDER FOR SOLUTION
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
23-09-2017
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
METHACHOLINE CHLORIDE
Tillgänglig från:
PANDA PHARMACEUTICALS INC.
ATC-kod:
V04CX
INN (International namn):
OTHER DIAGNOSTIC AGENTS
Dos:
100MG
Läkemedelsform:
POWDER FOR SOLUTION
Sammansättning:
METHACHOLINE CHLORIDE 100MG
Administreringssätt:
INHALATION
Enheter i paketet:
20ML/50ML
Receptbelagda typ:
Prescription
Terapiområde:
OTHER DIAGNOSTIC AGENTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0136042001; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2017-09-15
Produktens egenskaper
_Page 1 of 30 _
PRODUCT MONOGRAPH
PR
METHACHOLINE CHLORIDE, USP
Powder for inhalation solution
100 mg, 160 mg, 320 mg, 1280 mg and 1600 mg
Cholinergic / Diagnostic Aid (Bronchial Asthma)
Date of Preparation:
September 14, 2017
PANDA Pharmaceuticals.
35 Nixon Road
Caledon, Ontario
L7E 1K1
Control #204408
_Page 2 of 30 _
TABLE OF CONTENTS
PART
I
:
HEALTH PROFESSIONAL INFORMATION
.............................................................................
3
SUMMARY PRODUCT INFORMATION
...................................................................................................
3
INDICATIONS AND CLINICAL
USE.........................................................................................................
3
CONTRAINDICATIONS
..............................................................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................................................
4
ADVERSE REACTIONS
..............................................................................................................................
7
DRUG INTERACTIONS
...............................................................................................................................
7
DOSAGE AND ADMINISTRATION
...........................................................................................................
8
OVERDOSAGE
...........................................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................................
20
STORAGE AND STABILITY
....................................................................................................................
21
SPECIAL HANDLING INSTRUCTIONS
..................................................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
................
Läs hela dokumentet
